KIF20A is associated with clinical prognosis and synergistic effect of gemcitabine combined with ferroptosis inducer in lung adenocarcinoma

KIF20A is associated with clinical prognosis and synergistic effect of gemcitabine combined with ferroptosis inducer in lung adenocarcinoma

Gemcitabine (GEM), an antimetabolite that terminates DNA synthesis, is commonly used in the treatment of cancers including lung adenocarcinoma (LUAD). However, downregulation of sensitivity limits the therapeutic effect. Ferroptosis as the new form of regulated cell death has been shown to have grea...

Full description

Bibliographic Details
Main Authors: Hua He, Lu Liang, Jingjing Huang, Shiyao Jiang, Yueying Liu, Xiaoyan Sun, Yi Li, Li Cong, Yiqun Jiang
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-09-01
Series:Frontiers in Pharmacology
Subjects:
lung adenocarcinoma
gemcitabine
ferroptosis
synergistic effect
risk model
KIF20A
Online Access:https://www.frontiersin.org/articles/10.3389/fphar.2022.1007429/full

Internet

https://www.frontiersin.org/articles/10.3389/fphar.2022.1007429/full

Similar Items